Approved / ClinicalFDA-approvedApprovedUpdated 2026-04-24

Peptide reference file

Nesiritide

Trending #63 in Approved2.1k searches/moProven

Nesiritide is a recombinant B-type natriuretic peptide used in approved cardiovascular contexts.

Current readout: approved evidence, fda-approved status, approved approval state, human evidence appears in the current trail, registered trials are linked, and 3 linked sources in the seed trail.

PubChem CID 71308561 | 12623 PubMed results | 283 trial records | 0 DailyMed labels | 1 Drugs@FDA application

Nesiritide is mostly discussed because it expands the index into natriuretic-peptide biology and cardiovascular peptide therapeutics.

The public claim is straightforward: It expands the index into natriuretic-peptide biology and cardiovascular peptide therapeutics. Approved cardiovascular peptide medicine with direct human evidence.

In plain language, nesiritide is a recombinant B-type natriuretic peptide used in approved cardiovascular contexts.

ApprovedFDA-approved
Natriuretic peptideVasodilationHeart failure context

Aliases: Natrecor, B-type natriuretic peptide

SpecimenNesiritide specimen
CCCCHHHHHHHNOS
Formula
C143H244N50O42S4
Mass
3464.0
Evidence
Approved
Elements
5

Most commonly discussed in relation to Natriuretic peptide, Vasodilation, Heart failure context.

What Nesiritide is

Nesiritide is a recombinant B-type natriuretic peptide used in approved cardiovascular contexts.

Nesiritide is grouped under Approved / Clinical / Endogenous / Biology on PeptideFactCheck because it expands the index into natriuretic-peptide biology and cardiovascular peptide therapeutics.

The useful starting point is to separate the molecule itself from the internet story around it. It expands the index into natriuretic-peptide biology and cardiovascular peptide therapeutics.

Why people keep looking it up

It expands the index into natriuretic-peptide biology and cardiovascular peptide therapeutics.

Nesiritide is a recombinant B-type natriuretic peptide used in approved cardiovascular contexts.

Nesiritide tends to stay in the conversation because it touches a familiar public theme: natriuretic peptide, vasodilation, and heart failure context. That makes it easy for the claim to travel faster than the evidence.

What the evidence can support right now

Approved cardiovascular peptide medicine with direct human evidence.

Human trials and labeling support specific approved uses.

Mechanism follows natriuretic-peptide signaling and vasodilatory cardiovascular physiology.

Why this page carries the current tier: Approved cardiovascular peptide medicine with direct human evidence.

The current seed trail for Nesiritide is pulling from 1 labels source, 1 regulatory source, and 1 literature source.

Safety, limits, and regulatory context

This is a serious cardiovascular medicine context.

FDA-approved nesiritide products exist for specific indications.

Editorial boundary: PeptideFactCheck does not publish dosing, cycling, sourcing, injection, or administration instructions for Nesiritide. The job here is to explain the public claim, the mechanism story, the evidence strength, and the current limits.

Molecular and identifier data

The current PubChem match for Nesiritide is CID 71308561. That gives the page a source-backed chemistry record rather than a placeholder identifier block.

PubChem CID
71308561
Formula
C143H244N50O42S4
Molecular weight
3464.0
InChIKey
HPNRHPKXQZSDFX-OAQDCNSJSA-N

Matched synonyms include Nesiritide, 124584-08-3, nesiritida, nesiritidum, Nesiritide Recombinant, RefChem:164870, C01DX19, DTXCID501510760.

Open PubChem record

Clinical trial snapshot

The current ClinicalTrials.gov intervention query for Nesiritide returns 283 study records. This does not prove efficacy by itself, but it does show whether the peptide is showing up in a formal trial registry rather than only in forums or vendor copy.

Literature snapshot

The current PubMed query for Nesiritide returns 12623 results. The articles below are a quick literature surface so the page shows actual papers instead of only generic evidence labels.

Label and regulatory records

For approved or clinically developed peptides, the page now pulls in official labeling and FDA-facing records where they exist. That makes the regulatory section materially more useful than a generic approved or not-approved tag.

Source trail

Each linked source is shown directly so the page can be audited. The page now combines its editorial seed trail with automated official-source enrichment generated on 2026-04-24 from PubChem, ClinicalTrials.gov, PubMed, DailyMed, openFDA label, and Drugs@FDA.

Safety noteThis content is educational only and does not replace medical advice. Peptide use may carry risks and should be discussed with a qualified medical professional.